Our Programs


Our development programs represent the potential to improve the well-being of people whose lives are currently limited by rare disease.

BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Our lead development program is BCX10013*, a potentially once-daily, oral Factor D inhibitor for the treatment of complement-mediated diseases.

BioCryst’s discovery team is also designing oral drug candidates for additional targets in the classical, lectin and terminal pathways of complement.

For inquiries about licensing opportunities, please contact our business development group.

  • Lead Optimization

  • Pre-clinical



  • Approved / Commercial

Hereditary Angioedema (HAE)
Complement-Mediated Diseases
infectious diseases
Approved / Commercial

*BCX10013 is investigational and has not been deemed safe and effective by the FDA.